As domestic No. 1 immuno-cancer drug "Opdivo (Nivolumb)" renewed its contract with RSA, the benefit standard has also been expanded. The HIRA will issue a "proposal to revise the announcement of drugs prescribed and dispensed to cancer patients" and will inquire about their opinions by the 25th. If there is no disagreement, the benefit will be applied from the 1st of next month after the Health Insurance Policy Review Committee's resolution this week.

According to Opdivo-related standards, Yervoy (Ipilimumab) and combined therapy were recognized in the first stage of kidney cancer, and it was recognized in the second or more solo therapy for parietal cancer and the third or more Hodgkin lymphoma.